CRL
Charles River Laboratories International, Inc.Healthcare · $14.2B market cap
Verdict
Share price
$290.19
close of Oct 3, 2026
Fair value
$193.13
Sticker Price
Payback Price
$77.25
buy price
CRL is Overpriced: at $290.19 it trades 50% above its fair value of $193.13. Its buy price (Payback Price) is $77.25, 73% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 0% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow CRL
Get notified when it reaches its buy price of $77.25. Free.
Create a free accountSuperinvestors
2 of the investors we track hold CRL. In Q2 2026, 1 sold out. Who we track
Bill Nygren
Oakmark Funds · as of Q2 2026
$508.3M
2,241,144 shares
John Rogers
Ariel Investments · as of Q2 2026
$341.6M
1,506,185 shares
Moves in Q2 2026
Sold out: Lee Ainslie
Insider activity
Since Jun 29, 2026: no open-market purchases, 18 sales worth $42.6M and 13 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
FOSTER JAMES C
director · 2026-08-25
Sold
$10.1M
Parisotto Shannon M
CEVP, Disc & Safety Assessment · 2026-08-19
Sold
$600K
Andrews Nancy C
director · 2026-08-18
Sold
$163K
Parisotto Shannon M
CEVP, Disc & Safety Assessment · 2026-08-11
Sold
$1.0M
Girshick Birgit
Chief Executive Officer · 2026-08-11
Sold
$1.8M
Show all 18 salesShow fewer
FOSTER JAMES C
director · 2026-08-10
Sold
$7.9M
Creamer Victoria L
EVP & Chief People Officer · 2026-08-06
Sold
$1.1M
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$190K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$128K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$164K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$312K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$56K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$212K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$104K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$235K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Sold
$330K
Parisotto Shannon M
CEVP, Disc & Safety Assessment · 2026-08-05
Sold
$1.3M
FOSTER JAMES C
director · 2026-06-29
Sold
$16.9M
Other filings
FOSTER JAMES C
director · 2026-08-25
Option exercise
$4.1M
FOSTER JAMES C
director · 2026-08-25
Option exercise
$2.6M
Parisotto Shannon M
CEVP, Disc & Safety Assessment · 2026-08-19
Option exercise
$396K
Girshick Birgit
Chief Executive Officer · 2026-08-19
G-Gift
528 shares
Andrews Nancy C
director · 2026-08-18
Option exercise
$94K
Show all 13 other filingsShow fewer
Parisotto Shannon M
CEVP, Disc & Safety Assessment · 2026-08-11
Option exercise
$667K
Girshick Birgit
Chief Executive Officer · 2026-08-11
Option exercise
$1.2M
FOSTER JAMES C
director · 2026-08-10
Option exercise
$5.2M
LaPlume Joseph W
EVP, Corp Strategy & Develop · 2026-08-10
G-Gift
257 shares
Creamer Victoria L
EVP & Chief People Officer · 2026-08-06
Option exercise
$751K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Option exercise
$73K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Option exercise
$234K
Knell Michael Gunnar
SVP, Finance and CAO · 2026-08-06
Option exercise
$153K
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works